Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11307448 | 0.88 | GAA (0.55) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11182606 | 0.88 | CA12 (0.55) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11479346 | 0.85 | CA12 (0.59) | CA12CA1CA2CA3CA4 | |
| SCHEMBL9878198 | 0.83 | CA12 (0.46) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31515130 | 0.83 | NQO2 (0.46) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31515128 | 0.83 | NQO2 (0.46) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31124523 | 0.82 | CA12 (0.63) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31124522 | 0.82 | CA12 (0.63) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3131937 | 0.81 | CYP3A4 (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL4496856 | 0.81 | SLC9A1 (0.50) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| US-7504414-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | ARIENTI KRISTEN L | 2008-01-10 | — | — | US | disclosed |
| US-7271261-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1435947-B1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-¬4,5|-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO MCNEIL PHARM INC (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1435947-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHOMCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003032984-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDSI/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | CDKN1A, DDB1, TMBIM6 | CA12 4226/4885CA1 3264/4885CA2 3055/4885 |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, TMBIM6, CDS2 | CA12 4224/4885CA1 3412/4885CA2 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.